Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4332MR)

This product GTTS-WQ4332MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4332MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13024MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ9021MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ71MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ11593MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ3250MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ10365MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ13555MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ5074MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CaCP-29
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW